Neuroendocrine carcinoma of the prostate is a rare and aggressive form of prostate cancer that behaves very differently from the more common types of prostate disease. While typical prostate cancers respond to hormone treatments, this unusual variant often resists standard therapies and requires specialized approaches to diagnosis and care.

Understanding How Common This Disease Is

Neuroendocrine prostate cancer is exceptionally rare. It accounts for less than 2% of all prostate cancer cases, and small cell prostate carcinoma, a specific aggressive form, represents less than 0.5% to 1% of all prostate cancers.^[3][6] This rarity means many patients have never heard of this type of cancer before their diagnosis, and even some healthcare providers may have limited experience treating it.

The disease typically affects men in their 50s to 60s, though it can occur at any age.^[4] Interestingly, the number of cases appears to be rising, not necessarily because more men are developing the disease from the start, but because it’s increasingly recognized as a form of treatment resistance in men who initially had common prostate cancer and received modern hormone-blocking therapies.^[1][7]

Because of its rarity, neuroendocrine prostate cancer is often referred to as a “zebra” in medical communities. This reference comes from the medical saying “when you hear hoofbeats, think horses, not zebras,” which encourages doctors to consider common diseases first. Just like zebra stripes, no two cases of this cancer are exactly alike, making each patient’s journey unique.^[3]

What Causes This Type of Cancer

Neuroendocrine carcinoma of the prostate can arise in two distinct ways. The first is called de novo, which is a Latin term meaning “from the beginning.” In these cases, the cancer develops as neuroendocrine carcinoma from the start, without any previous history of typical prostate cancer.^[3][10]

However, the more common pathway is what scientists call treatment-related or treatment-emergent neuroendocrine prostate cancer. This occurs when a typical prostate cancer transforms into a neuroendocrine type during the course of treatment, particularly after exposure to powerful hormone therapies that block androgen receptor (AR) signaling—the pathway that normally fuels prostate cancer growth.^[1] Drugs such as abiraterone acetate or enzalutamide are designed to starve prostate cancer cells by blocking their access to male hormones, but in some cases, cancer cells find an escape route by changing their very nature.

This transformation is an example of what researchers call lineage plasticity. This means the cancer cells essentially change their identity, switching from one cell type to another as a survival strategy.^[1][7] When prostate adenocarcinoma cells undergo this change, they lose their dependence on male hormones and adopt characteristics of neuroendocrine cells, which are normally found throughout the body and help regulate various functions through hormone-like chemicals.

The normal prostate gland does contain about 1% neuroendocrine cells naturally, which are part of the body’s diffuse hormone-producing cell system. These cells help with prostate growth and function under normal circumstances.^[4] However, when cancer develops from or transforms into these cell types, the disease takes on an aggressive character that makes it difficult to treat.

Risk Factors for Developing This Cancer

Understanding who is at higher risk for developing neuroendocrine prostate cancer can help with earlier detection. Men who have been treated with hormone-blocking therapies for advanced prostate cancer face the highest risk of developing treatment-related neuroendocrine transformation. Studies suggest that up to 15% to 20% of men with castration-resistant prostate cancer who have been treated with potent drugs targeting the androgen receptor may develop features of androgen receptor independence, which can include neuroendocrine changes.^[7]

Certain genetic changes in the original prostate cancer may make transformation more likely. Loss of function in two important tumor suppressor genes—proteins that normally help prevent cancer growth—called RB1 and TP53 appears to be a key facilitator of the transformation process.^[1] When both of these protective genes stop working properly, cancer cells may find it easier to change their identity and become neuroendocrine in nature.

Men with advanced or metastatic prostate cancer, meaning cancer that has spread beyond the prostate to other parts of the body, are at higher risk. The disease is commonly found to have already spread at the time of diagnosis, with metastases often appearing in bones, lymph nodes, liver, and lungs.^[6]

Extended exposure to multiple lines of hormone therapy may also increase risk, as the cancer cells under constant pressure to survive despite hormone blockade may eventually find alternative growth pathways. This doesn’t mean men should avoid necessary hormone treatments, but rather emphasizes the importance of close monitoring during therapy.

Recognizing the Symptoms

The symptoms of neuroendocrine prostate cancer often differ significantly from typical prostate cancer, and they tend to appear more suddenly and progress more rapidly. One striking feature is that traditional markers used to monitor prostate cancer may not be elevated. Many men with this form of cancer have normal or low levels of PSA (prostate-specific antigen), a protein typically elevated in prostate cancer.^[1] This can make the cancer harder to detect through routine PSA blood tests.

Patients may experience rapid and unexplained weight loss over a relatively short period, sometimes losing 20 pounds or more within months.^[6] This weight loss is often accompanied by a general feeling of unwellness, fatigue, and loss of appetite.

Respiratory symptoms can occur when the disease spreads to the lungs or chest area. Men may develop persistent cough, shortness of breath, or difficulty breathing.^[6] Some patients experience night sweats and unexplained fevers that don’t respond to antibiotics, which can initially mislead doctors into suspecting an infection rather than cancer.

Pain is often a significant symptom, particularly severe back pain. This can occur when cancer spreads to the spine or puts pressure on nerves. In some cases, the cancer can cause near spinal cord compression, a medical emergency that requires immediate attention.^[6] Bone pain in other areas is also common as the cancer frequently spreads to bones throughout the body.

When the disease affects the liver, patients may develop symptoms related to liver dysfunction, including yellowing of the skin or eyes (jaundice), abdominal swelling, or pain in the upper right abdomen. Some men may notice swelling in their legs due to fluid retention or blocked lymphatic drainage.

The aggressive nature of this cancer means symptoms often progress quickly, sometimes over weeks to months rather than the years-long course typical of common prostate adenocarcinoma. This rapid progression requires prompt medical attention and thorough evaluation when new or worsening symptoms appear.

Prevention and Early Detection Strategies

Because neuroendocrine prostate cancer is so rare and its transformation from adenocarcinoma involves complex biological changes, there are no specific prevention strategies proven to stop it from developing. However, certain approaches may help with earlier detection, particularly for men already being treated for prostate cancer.

For men receiving hormone therapy for prostate cancer, maintaining regular follow-up appointments is crucial. If PSA levels are stable or dropping but new symptoms appear—such as rapid weight loss, bone pain, breathing difficulties, or unexplained fatigue—these should be reported immediately to the healthcare team. The appearance of aggressive symptoms despite good PSA control can be a warning sign of transformation.^[1]

If symptoms suggest disease progression despite hormone therapy, requesting additional testing may be appropriate. This might include imaging studies to look for new areas of cancer spread or, in some cases, a biopsy of a metastatic site to examine the cancer cells under a microscope. Accurate diagnosis requires expert review of tissue samples, as neuroendocrine prostate cancer can be difficult to distinguish from typical prostate cancer without specialized examination.^[3]

Men being treated for prostate cancer should be aware of their treatment history and keep records of which therapies they have received. This information helps doctors recognize patterns that might increase risk for transformation. Open communication with healthcare providers about all symptoms, even those that seem unrelated to prostate cancer, ensures nothing important is overlooked.

Maintaining overall health through balanced nutrition, regular physical activity within individual capabilities, and avoiding tobacco can support the body’s general resilience, though these measures have not been specifically proven to prevent neuroendocrine transformation. Stress management and maintaining emotional well-being are also important aspects of living with any form of cancer.

How the Disease Changes Normal Body Functions

Understanding what happens in the body when neuroendocrine prostate cancer develops helps explain why the disease behaves so differently from typical prostate cancer. At the heart of these changes is the loss of dependence on male hormones, particularly testosterone and its derivative dihydrotestosterone, which normally drive prostate cancer growth.

In typical prostate adenocarcinoma, cancer cells rely heavily on the androgen receptor to receive signals from male hormones that tell them to grow and divide. Hormone-blocking therapies work by cutting off these signals. However, in neuroendocrine prostate cancer, the cells essentially learn to live without this signaling pathway. The cancer cells downregulate or stop producing the androgen receptor entirely, along with PSA and another important marker called PSMA (prostate-specific membrane antigen).^[1]

This transformation involves profound changes at the genetic and epigenetic level—meaning both changes in the DNA sequence itself and changes in how genes are turned on or off without altering the DNA code. One significant change involves increased activity of a protein called EZH2, which helps control which genes are expressed. When EZH2 becomes overactive, it can help drive the transformation to a neuroendocrine state.^[1]

The cancer cells begin expressing different proteins and markers characteristic of neuroendocrine cells. These include substances like chromogranin, synaptophysin, and neuron-specific enolase, which are normally found in cells of the nervous system and hormone-producing cells scattered throughout the body.^[6] The cells may develop long, branching processes similar to nerve cells and start producing various hormones or hormone-like substances.

Special transcription factors—proteins that act as master switches for gene expression—become activated during transformation. These include SOX2, ASCL1, and BRN2, which are normally involved in determining cell fate during development. Their activation helps reprogram prostate cancer cells into neuroendocrine cells.^[1]

The transformed cancer cells often grow more rapidly and aggressively than typical prostate cancer. They more readily invade surrounding tissues and spread to distant organs. The pattern of spread may differ, with a higher likelihood of metastases to unusual sites like the liver or lungs, in addition to the bone metastases common in regular prostate cancer.

Because these cells no longer depend on male hormones, they continue growing despite castration levels of testosterone, whether achieved through medication or surgery. This explains why hormone therapy that would normally slow or stop prostate cancer growth has little effect on neuroendocrine prostate cancer. The cancer has essentially found an escape route around the blockade.

The biological changes also affect how the cancer responds to various treatments. Standard hormone therapies become ineffective. Chemotherapy regimens similar to those used for small cell lung cancer, which shares biological features with neuroendocrine prostate cancer, are often employed instead. These typically include platinum-based drugs combined with other chemotherapy agents.^[6][10]

Understanding these fundamental changes has opened new avenues for research. Scientists are investigating whether targeting the epigenetic changes, blocking the master switch transcription factors, or exploiting vulnerabilities specific to neuroendocrine cells might lead to more effective treatments in the future.^[1][7]